Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Completed 4

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 4Carcinoma, Renal Cell 4Prostatic Hyperplasia 1Neoplasms 1Neoplasm Metastasis 1Kidney Neoplasms 1

Interventions

Sunitinib 145Nivolumab 144pembrolizumab 132Sorafenib 84Bevacizumab 77Everolimus 74cabozantinib 71pazopanib 65Axitinib 65Ipilimumab 62aldesleukin 52Magnetic Resonance Spectroscopy 45Cyclophosphamide 40Interleukin-2 38lenvatinib 37Specimen Handling 36Radiosurgery 36Interferon-alpha 32atezolizumab 30temsirolimus 27belzutifan 24Gemcitabine 23fludarabine phosphate 22avelumab 22Radiotherapy 19Interferon alpha-2 19Biopsy 18fludarabine 17durvalumab 17Nephrectomy 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × TroVax × Genitourinary × Clear all
NCT00083941 2020-10-19

A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer

Oxford BioMedica

Phase 2 Completed
25 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT00325507 2020-10-19

Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma

Oxford BioMedica

Phase 2 Completed
25 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT00397345 2020-10-19

TroVax Renal Immunotherapy Survival Trial

Oxford BioMedica

Phase 3 Completed
733 enrolled
Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms

NCT00445523 2016-03-17

Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer

The Methodist Hospital Research Institute

Phase 2 Completed
28 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡